Role of biological targeted therapies in gastroenteropancreatic neuroendocrine tumours. - Wikidata - awgldk - TriplyDB

Role of biological targeted therapies in gastroenteropancreatic neuroendocrine tumours.

Role of biological targeted therapies in gastroenteropancreatic neuroendocrine tumours.

http://www.wikidata.org/entity/Q37922650

about

Ectopic acromegaly due to growth hormone releasing hormone.Diagnostic performance of Gallium-68 somatostatin receptor PET and PET/CT in patients with thoracic and gastroenteropancreatic neuroendocrine tumours: a meta-analysis.Everolimus and mTOR inhibition in pancreatic neuroendocrine tumors.Investigational drugs targeting somatostatin receptors for treatment of acromegaly and neuroendocrine tumors.PI3K/Akt/mTOR signaling in medullary thyroid cancer: a promising molecular target for cancer therapy.Valproic acid induces NET cell growth arrest and enhances tumor suppression of the receptor-targeted peptide-drug conjugate via activating somatostatin receptor type II.'Open-and-close' pituitary surgery in an acromegalic man presenting with excessive sweatiness.Somatostatin analogs in the treatment of neuroendocrine tumors: current and emerging aspects.Secondary malignancy in patients with sporadic neuroendocrine neoplasia.Initial impact of a systematic multidisciplinary approach on the management of patients with gastroenteropancreatic neuroendocrine tumor.

P2860

Q36557139-5400425D-3BDC-4224-AEEC-88DF52AA5B63 Q37986605-D174A427-33BC-48DE-B16A-60F5FDC0B5C0 Q38035844-2FA1F759-FF9C-4D25-BEA0-9053EC0C9F52 Q38233686-06FACA26-B498-49E9-8CB7-70A0F5CFF845 Q38239229-165E25D8-4A7C-4BF3-9A67-6E1FB138D10D Q38849324-E9DB5F54-24B1-4C16-B379-AF352B6B4420 Q48685321-B86A6C1D-237E-4D6F-B602-EE16B00548BC Q50079728-008E4FDB-51D9-421F-B584-A4799720F2E6 Q51263169-0B711179-CFC2-4BE2-9C31-68844B0188F9 Q53114629-1479BE33-EDFF-4BB5-B709-4990E8EB1F80

P2860

Role of biological targeted therapies in gastroenteropancreatic neuroendocrine tumours.

http://www.wikidata.org/entity/Q37922650

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Role of biological targeted therapies in gastroenteropancreatic neuroendocrine tumours.

@en

Role of biological targeted therapies in gastroenteropancreatic neuroendocrine tumours.

@nl

type

label

Role of biological targeted therapies in gastroenteropancreatic neuroendocrine tumours.

@en

Role of biological targeted therapies in gastroenteropancreatic neuroendocrine tumours.

@nl

prefLabel

Role of biological targeted therapies in gastroenteropancreatic neuroendocrine tumours.

@en

Role of biological targeted therapies in gastroenteropancreatic neuroendocrine tumours.

@nl

P1433

Q37922650-34C05522-1F4B-4CC8-A795-8D3AFEF1197A

P1476

Q37922650-6B162E90-09C1-433C-BC64-0CD6B96F17A5

P2093

Q37922650-30EA55C3-5254-4180-9023-5BFC9FDB3FD3

P2860

Q37922650-0EC7AC8B-93CB-411C-9001-6DA425941144

Q37922650-2103BD27-EAC8-42FF-8AEB-A44A4057F885

Q37922650-21FC31F5-2292-4163-AF15-B8B28AB0D1B4

Q37922650-243F6096-1D4F-43AC-A078-AF242792781D

Q37922650-2818DB1A-1090-44F8-AF26-03BC3A316753

Q37922650-344221AF-FF1D-4E15-9A08-1E3157D43013

Q37922650-3DC2D43C-88FA-48AC-81D3-CCF458FDEFBB

Q37922650-418F4C87-B90C-4431-A392-FBD722CF5696

Q37922650-42E7DCC8-5332-4446-9A8D-44EEBD1DA50C

Q37922650-5D2BB431-6F7A-4A4F-B180-CA309BB782AF

P2888

Q37922650-E9E0E221-CB08-4D9B-894F-E0EA02869834

P304

Q37922650-6CF6A5A9-36D1-4B95-8F87-273841180132

P31

Q37922650-7C0E4040-90E1-41A6-84FE-3DDC09AEDE29

P356

Q37922650-E5A726F9-9130-40F7-AB2C-CC3614E458BD

P433

Q37922650-4082FA8A-CED2-4C0C-AC82-CBEE3C442C15

P478

Q37922650-3EDFFA98-E609-41C6-9E97-9191362A7F83

P577

Q37922650-F07BC878-3E69-4EF8-8DFD-CFDA2BB04FBF

P698

Q37922650-7DD375AA-75A3-432B-8758-77C4AD01FBFB

P356

S12020-011-9513-Y

P1433

P1476

Role of biological targeted therapies in gastroenteropancreatic neuroendocrine tumours.

@en

P2093

Kein-Leong Yim

http://www.w3.org/2001/XMLSchema#string

P2860

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1.

Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.

Everolimus for advanced pancreatic neuroendocrine tumors.

Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial.

A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas

Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study

Emerging strategies to strengthen the anti-tumour activity of type I interferons: overcoming survival pathways.

Effects of type I interferons on IGF-mediated autocrine/paracrine growth of human neuroendocrine tumor cells.

P2888

s12020-011-9513-y

P304

181-186

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S12020-011-9513-Y

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

40

http://www.w3.org/2001/XMLSchema#string

P577

2011-08-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21870172

http://www.w3.org/2001/XMLSchema#string